Comparative Pharmacology
Head-to-head clinical analysis: RECTIV versus TRIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECTIV versus TRIDIL.
RECTIV vs TRIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (cGMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
Nitroglycerin is a vasodilator that acts directly on vascular smooth muscle, causing relaxation. It primarily dilates venous capacitance vessels, reducing preload, and at higher doses dilates arterioles, reducing afterload. The mechanism involves nitric oxide-mediated activation of guanylyl cyclase, increasing cGMP levels.
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
Initial adult dose: 5 mcg/min IV via continuous infusion, titrated by 5 mcg/min every 3-5 minutes to achieve desired effect; usual therapeutic range 10-200 mcg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Terminal elimination half-life of nitroglycerin is 1-4 minutes; clinical effects are limited by rapid metabolism
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Renal (87% as inorganic nitrite/nitrate and metabolites), biliary/fecal (minimal, <1%)
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator